Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer

Weickhardt, AJ; Lau, DK; Hodgson-Garms, M; Lavis, A; Jenkins, LJ; Vukelic, N; Ioannidis, P; Luk, IY; Mariadason, JM

Weickhardt, AJ; Mariadason, JM (通讯作者)，Olivia Newton John Canc & Res Inst, Melbourne, Vic, Australia.;Weickhardt, AJ; Mariadason, JM (通讯作者)，La Trobe Univ, Sch Canc Med, Melbourne, Vic, Australia.;Weickhardt, AJ; Mariadason, JM (通讯作者)，Austin Hlth, Dept Med Oncol, Olivia Newton John Canc Wellness & Res Ctr, Melbourne, Vic, Australia.;Mariadason, JM (通讯作者)，Univ Melbourne, Dept Med, Austin Hlth, Melbourne, Vic, Australia.

BMC CANCER, 2022; 22 (1):

Abstract

Background Mutations and fusions in Fibroblast Growth Factor Receptor 3 (FGFR3) occur in 10-20% of metastatic urothelial carcinomas and confer sensiti......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索